|
URL:
http://www.mapinc.org/drugnews/v04/n1463/a01.html
Pubdate: Thu, 14 Oct 2004
Source: NOW Magazine (CN ON)
Copyright: 2004 NOW Communications Inc.
Website: http://www.nowtoronto.com/
Author: Paul Armentano
Bookmark: http://www.mapinc.org/mmj.htm
(Cannabis - Medicinal)
CANCER KILLER
U.S. War on Drugs Stalling Mind-Blowing Research into Pot's
Cancer-Healing Properties
Clinical research published in a journal of the American Association for
Cancer Research showing that marijuana's
components can inhibit the growth of cancerous brain tumours is
the latest in a long line of studies demonstrating the drug's potential
as an anti-cancer agent.
This latest study, performed by researchers at Madrid's Complutense
University, found that cannabis restricts the blood supply to
glioblastoma multiforme tumours, an aggressive brain tumour that kills
some 7,000 people in the United States every year. But despite the
value of such findings both in terms of the treatment of
life-threatening illnesses and as news, U.S. media coverage has
been almost non-existent.
Why the blackout? Not one such study has been acknowledged by the U.S.
government.
This wasn't always the case. In fact, the first experiment
documenting pot's anti-tumour effects took place in 1974 at the Medical
College of Virginia at the behest of the U.S. government.
It showed that marijuana's psychoactive component, THC, "slowed the
growth of lung cancers, breast cancers and a virus-induced leukemia in
laboratory mice and prolonged their lives by as much as 36 per
cent."
Despite these favourable preliminary findings, U.S. government
officials refused to fund any follow-up research for two decades, until
it conducted a similar - though secret - clinical trial in the
mid-1990s.
That study, carried out by the U.S. National Toxicology Program,
concluded that mice and rats administered high doses of THC over long
periods had greater protection against malignant tumours than untreated
controls.
Rather than publicize these findings, government researchers shelved the
results, which only became public after a draft copy of the findings
were leaked in 1997 to a medical journal that in turn forwarded the
story to the national media.
However, in the eight years since then, the U.S. government has
yet to fund a single additional study examining the drug's potential
anti-cancer properties. Is this a case of federal bureaucrats
valuing politics more than the health and safety of patients? You be the
judge.
Fortunately, scientists overseas have generously picked up where U.S.
researchers so abruptly left off.
This month, researchers at the University of Milan in Italy, reported
that marijuana's constituents inhibit the spread of brain cancer in
human tumour biopsies from patients failed by standard cancer therapies.
Last year, the same researchers reported in the Journal of Pharmacology
and Experimental Therapeutics that non-psychoactive compounds in
marijuana inhibited the growth of glioma cells in a dose-dependent
manner and selectively targeted and killed malignant cells, stimulating
them to "commit suicide" in a natural process called
apoptosis.
In 2000, a research team at Complutense's department of biochemistry and
molecular biology reported in the journal Nature Medicine that
injections of synthetic THC eradicated malignant gliomas ( brain tumours
) in one-third of treated rats. The study was undertaken after the
discovery in 1998 that THC can selectively induce apoptosis in brain
tumour cells without negatively affecting the surrounding healthy cells.
Nevertheless, federal officials in the U.S. continue to refuse to
express any interest in funding - or even acknowledging - this clinical
research.
MAP
posted-by: Tom Smith
Return
to Pot News
|